Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Gynecol Oncol Rep. 2020 Jun 15;33:100600. doi: 10.1016/j.gore.2020.100600. eCollection 2020 Aug.


•Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab.•The tumor was massively infiltrated by CD8+ T cells while PD-L1 TPS was at 10%.•CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

Keywords: CCL5; CD8; CSMD3; CXCL9; High-grade serous ovarian carcinoma; Immunotherapy; PD1; Pembrolizumab.

Publication types

  • Case Reports